Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Shares Down 1.1% - Should You Sell?

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report)'s share price fell 1.1% during mid-day trading on Tuesday . The company traded as low as $8.14 and last traded at $8.30. 52,012 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 117,397 shares. The stock had previously closed at $8.39.

Shionogi & Co., Ltd. Price Performance

The company's 50-day moving average is $8.06 and its two-hundred day moving average is $7.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.64 and a quick ratio of 7.01. The firm has a market cap of $14.29 billion, a P/E ratio of 13.93, a PEG ratio of 2.37 and a beta of 0.19.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.03). Shionogi & Co., Ltd. had a return on equity of 12.02% and a net margin of 35.53%. The firm had revenue of $721.77 million for the quarter, compared to the consensus estimate of $824.23 million. Sell-side analysts anticipate that Shionogi & Co., Ltd. will post 0.66 EPS for the current fiscal year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.